The standards of care for relapsed ovarian cancer are not well determined. Given the results of three parallel randomized clinical trials（SOC-1，DESKTOP 3，and GOG-0213）on the efficacy of secondary cytoreductive surgery，patients with relapsed ovarian cancer who have received one previous therapy should be counselled about the options of secondary cytoreduction in specialized centers with high volumes of ovarian cancer surgery. An ideal patient selection algorithm should be implemented to filter right candidates. Meanwhile，an inappropriate decision on surgery could be detrimental. An individual therapy should be clearly indicated for each of patients. Secondary cytoreductive surgery is just a part of systemic therapies for ovarian cancer，and state of the art therapy for relapse comes from standard of care of the first-line therapy. In china，it’s a long way.